Alnylam Adding Patients to ATTR Trial, Conducting Interim Analysis of RSV Data

Alnylam also released its first-quarter financial results, reporting higher losses and lower revenues.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.